Topical Liposomal Amphotericin B Gel Treatment for Cutaneous Leishmaniasis

Topical Liposomal Amphotericin B Gel Treatment for Cutaneous Leishmaniasis

Comparison between placebo gel treatment to topical liposomal amphotericin B gel treatment for cutaneous leishmaniasis of Leishmania species major and tropica.

Randomized, double blind, placebo controlled study. The study will include 108 patients with cutenous leishmaniasis of Leishmania species major and tropica, confired by Polymerase Chain Reaction of a sample from a lesion.

Cure rate will be compared between patients treated with Amphotericin-B 0.4% Liposomal Gel and patients treated with placebo gel preparation.

Inclusion Criteria:

• Cutenous leishmaniasis confirmed by PCR (Leishmania species major or tropica)
• 1 to 5 lesions
• Signed informed consent

Exclusion Criteria:

• Facial lesions
• Significant co-morbidity
• Pregnancy or breast-feeding at enrollment
• Previous treatment for leishmaniasis